The primary purpose of the Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents text is to offer students, clinicians, scientists, and members of the pharmaceutical industry a comprehensive yet practical information resource for medications that affect the central nervous system (CNS). Part 1 presents the background for the pharmacokinetic and pharmacodynamic principles for agents that must reach the CNS to produce their clinical actions. Drug development and clinical application for the psychopharmacological agents have progressed to incorporate biomarkers, such as positron emission tomography (PET) scans, pharmacogenomics, and sophisticated mathematical modeling with population pharmacometrics. These chapters provide the readers with a foundational background of these exciting areas. Each chapter in Part 2 offers an important focus on psychopharmacological agents that reinforces the basic principles in Part 1 .
The Part 2 chapters portray a broad scope of psychopharmacological agents that are available in different formulations, such as long-acting injectable antipsychotics and oral extended-release products; these formulations promote ease of dosing administration and enhance patient adherence. Some of the earliest worksof pharmacokinetic- pharmacodynamic modeling occurred with the anesthetic agents, which formed the basis of analysis for the remaining psychopharmacologic medications. Pharmacodynamic parameters assessing CNS drug effects are challenging and frequently involve a variety of measurements. These measurements include patient clinical rating scales for effi cacy and adverse effects, serum drug concentrations, physiologic assessments, pharmacogenomic markers, and imaging technologies.
The chapters in Part 3 concentrate on drug-drug interactions with psychopharmacological agents. Drug-drug interactions with CNS agents can occur via pharmacokinetic and/or pharmacodynamic mechanisms. Part 3 serves as a valuable resource to aid clinicians discerning clinically signifi cant drug-drug interactions commonly encountered in patient care
The editors wish to acknowledge our sincere appreciation to the chapter authors who contributed their time, effort, and enthusiasm, all of which made this book possible. Finally, the editors would like to thank their spouses and family members for their support during the long hours spent completing this endeavor.
Fort Worth, TX, USA Michael W. Jann
Scott R. Penzak
Lawrence J. Cohen